Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France
•We aimed to describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 as well as patients’ characteristics related to the use of protease inhibitors in 2015. We extracted data from 15,897 patients who started a first antiretroviral therapy between 2005 and 201...
Gespeichert in:
| Veröffentlicht in: | Médecine et maladies infectieuses 2019-06, Vol.49 (4), p.264-269 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 4 |
| container_start_page | 264 |
| container_title | Médecine et maladies infectieuses |
| container_volume | 49 |
| creator | Pugliese, P. Joly, V. Valantin, M.A. Cotte, L. Huleux, T. Allavena, C. Reynes, J. Poizot-Martin, I. Bani-Sadr, F. Cuzin, L. |
| description | •We aimed to describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 as well as patients’ characteristics related to the use of protease inhibitors in 2015. We extracted data from 15,897 patients who started a first antiretroviral therapy between 2005 and 2015. Before 2014, 60% of initial treatment regimens were based on boosted protease inhibitors. The use of integrase strand transfer inhibitors as first-line treatments was recommended in 2014, and they have since been gradually replacing boosted protease inhibitors in the first-line treatment setting. In 2015, boosted protease inhibitors were still more frequently prescribed to young women, patients with high viral loads, and patients low CD4 cell counts.
To describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 and patients’ characteristics related to the use of protease inhibitors in 2015.
We extracted all patients starting ART between 2005 and 2015 from a large prospective cohort. Regimens were classified as three nucleoside reverse transcriptase inhibitors (NRTI), or two NRTIs with a boosted protease inhibitor (bPI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI), or with an INSTI. Patients’ characteristics at the time of initiation were collected. A multinomial logit model was fitted to analyze characteristics related to the choice of regimen in 2015.
We analyzed data from 15,897 patients. The proportion of patients starting with (i) a bPI decreased from 60% before 2014 to 38.1% in 2015; (ii) an NNRTI decreased from 30% to 17.8% in 2015; (iii) an INSTI gradually increased to 39.4% in 2015. In 2015, patients with an initial viral load ˃5 log copies/mL were less likely to receive NNRTI (OR=0.08) or INSTI regimens (OR=0.69) than bPIs. Patients with initial CD4+ T cell count ˂200/mm3 were less likely to receive an NNRTI (OR=0.28) or an INSTI regimen (OR=0.52) than a bPI. Women were less likely to receive an NNRTI (OR=0.79) or an INSTI regimen (OR=0.71) than a bPI; although this depended on age.
The use of bPI as first-line ART declined sharply in France from 2005 to 2015. bPI remained of preferential use in patients with high viral load, low CD4+ T cell count, and in women.
Décrire les choix de premier traitement antirétroviral en France entre 2005 et 2015 et analyser les caractéristiques liées à l’utilisation d’inhibiteurs de protéase (IP) en 2015.
Tous les patients ayant débuté leur traitement entre le 01 |
| doi_str_mv | 10.1016/j.medmal.2018.10.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03261312v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0399077X17305449</els_id><sourcerecordid>2132224538</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-7dd476e3b7a144f32896a3a2aa2b142d0201ba49115b3e84697779ec9719788b3</originalsourceid><addsrcrecordid>eNp9kc2LFDEQxYMo7rj6H4jk6B56rHxMp3NRlsF1hQEvit5CdbrGztAfY5IZ2P_eDL3u0VPg5fdeUfUYeytgLUDUHw7rkboRh7UE0RRpDbB5xlbC1LaqawvP2QqUtRUY8-uKvUrpACALCy_ZlQINdqPFio0_--B7jlMOkXKczyHikHjq59PQ8Zb4MVLyMbTUcUx8H2LK1RAm4jkS5pGmnD7xbY_Tb0p8PlPkuS8uTJkL4A-EMfEw8buIk6fX7MW-xNObx_ea_bj7_H17X-2-ffm6vd1VXmuZK9N12tSkWoNC672Sja1RoUSUrdCyg7JGi9oKsWkVNbq2xhhL3hphTdO06prdLLk9Du4Yw4jxwc0Y3P3tzl00ULIWSsizKOz7hT3G-c-JUnZjSJ6GASeaT8lJoaSUeqOaguoF9XFOKdL-KVuAu5TiDm4pxV1KuaillGJ79zjh1JbvJ9O_FgrwcQGo3OQcKLrkA5V7daUUn103h_9P-As9s536</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2132224538</pqid></control><display><type>article</type><title>Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pugliese, P. ; Joly, V. ; Valantin, M.A. ; Cotte, L. ; Huleux, T. ; Allavena, C. ; Reynes, J. ; Poizot-Martin, I. ; Bani-Sadr, F. ; Cuzin, L.</creator><creatorcontrib>Pugliese, P. ; Joly, V. ; Valantin, M.A. ; Cotte, L. ; Huleux, T. ; Allavena, C. ; Reynes, J. ; Poizot-Martin, I. ; Bani-Sadr, F. ; Cuzin, L. ; Dat’AIDS group</creatorcontrib><description>•We aimed to describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 as well as patients’ characteristics related to the use of protease inhibitors in 2015. We extracted data from 15,897 patients who started a first antiretroviral therapy between 2005 and 2015. Before 2014, 60% of initial treatment regimens were based on boosted protease inhibitors. The use of integrase strand transfer inhibitors as first-line treatments was recommended in 2014, and they have since been gradually replacing boosted protease inhibitors in the first-line treatment setting. In 2015, boosted protease inhibitors were still more frequently prescribed to young women, patients with high viral loads, and patients low CD4 cell counts.
To describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 and patients’ characteristics related to the use of protease inhibitors in 2015.
We extracted all patients starting ART between 2005 and 2015 from a large prospective cohort. Regimens were classified as three nucleoside reverse transcriptase inhibitors (NRTI), or two NRTIs with a boosted protease inhibitor (bPI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI), or with an INSTI. Patients’ characteristics at the time of initiation were collected. A multinomial logit model was fitted to analyze characteristics related to the choice of regimen in 2015.
We analyzed data from 15,897 patients. The proportion of patients starting with (i) a bPI decreased from 60% before 2014 to 38.1% in 2015; (ii) an NNRTI decreased from 30% to 17.8% in 2015; (iii) an INSTI gradually increased to 39.4% in 2015. In 2015, patients with an initial viral load ˃5 log copies/mL were less likely to receive NNRTI (OR=0.08) or INSTI regimens (OR=0.69) than bPIs. Patients with initial CD4+ T cell count ˂200/mm3 were less likely to receive an NNRTI (OR=0.28) or an INSTI regimen (OR=0.52) than a bPI. Women were less likely to receive an NNRTI (OR=0.79) or an INSTI regimen (OR=0.71) than a bPI; although this depended on age.
The use of bPI as first-line ART declined sharply in France from 2005 to 2015. bPI remained of preferential use in patients with high viral load, low CD4+ T cell count, and in women.
Décrire les choix de premier traitement antirétroviral en France entre 2005 et 2015 et analyser les caractéristiques liées à l’utilisation d’inhibiteurs de protéase (IP) en 2015.
Tous les patients ayant débuté leur traitement entre le 01/01/2005 et le 31/12/2015 et suivis dans la cohorte Dat’AIDS ont été inclus. Les schémas thérapeutiques ont été classés comme suit : trois analogues nucléosidiques (NRTI), deux NRTI avec un IP boosté (IPb), avec un analogue non nucléosidique (NNRTI) ou avec un inhibiteur de l’intégrase (INSTI). Les caractéristiques des patients à l’instauration du traitement ont été recueillies. Un modèle multinomial a été construit afin d’analyser les caractéristiques liées à la prescription d’IPb en 2015.
Au total, 15 897 patients analysés. La proportion de patients recevant un IPb est passée de 60 % avant 2014 à 38,1 % en 2015 et celle recevant un NNRTI a diminué de 30 % à 17,8 % en 2015. L’utilisation d’INSTI a progressivement augmenté jusqu’à 39,4 % en 2015. En 2015, les patients ayant une charge virale>5 log/mL recevaient moins souvent un NNRTI (OR=0,08) ou un INSTI (OR=0,69) qu’un IPb. Les patients ayant moins de 200 CD4/mm3 recevaient moins souvent un NNRTI (OR=0,28) ou un INSTI (OR=0,52) qu’un IPb. Les femmes recevaient moins souvent un NNRTI (OR=0,79) ou un INSTI (OR=0,71) qu’un IPb, cela dépendait aussi de leur âge.
L’utilisation d’IPb a significativement diminué au cours de la dernière décennie, mais reste préférée en cas de CD4 bas, de charge virale élevée ou chez les femmes.</description><identifier>ISSN: 0399-077X</identifier><identifier>EISSN: 1769-6690</identifier><identifier>DOI: 10.1016/j.medmal.2018.10.005</identifier><identifier>PMID: 30409541</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Adult ; Anti-HIV Agents - therapeutic use ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral Therapy, Highly Active - statistics & numerical data ; Cohort Studies ; Drug Therapy, Combination ; Female ; France - epidemiology ; History, 21st Century ; HIV ; HIV infection ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Protease Inhibitors - therapeutic use ; Human health and pathology ; Humans ; Infection par le VIH ; Inhibiteurs d’intégrase ; Initial HIV therapy ; Integrase strand transfer inhibitors ; Life Sciences ; Male ; Middle Aged ; Practice Patterns, Physicians' - history ; Practice Patterns, Physicians' - statistics & numerical data ; Practice Patterns, Physicians' - trends ; Reverse Transcriptase Inhibitors - therapeutic use ; Traitement antirétroviral initial ; Viral Load</subject><ispartof>Médecine et maladies infectieuses, 2019-06, Vol.49 (4), p.264-269</ispartof><rights>2018 Elsevier Masson SAS</rights><rights>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-7dd476e3b7a144f32896a3a2aa2b142d0201ba49115b3e84697779ec9719788b3</citedby><cites>FETCH-LOGICAL-c442t-7dd476e3b7a144f32896a3a2aa2b142d0201ba49115b3e84697779ec9719788b3</cites><orcidid>0000-0002-6345-497X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0399077X17305449$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30409541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-reims.fr/hal-03261312$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pugliese, P.</creatorcontrib><creatorcontrib>Joly, V.</creatorcontrib><creatorcontrib>Valantin, M.A.</creatorcontrib><creatorcontrib>Cotte, L.</creatorcontrib><creatorcontrib>Huleux, T.</creatorcontrib><creatorcontrib>Allavena, C.</creatorcontrib><creatorcontrib>Reynes, J.</creatorcontrib><creatorcontrib>Poizot-Martin, I.</creatorcontrib><creatorcontrib>Bani-Sadr, F.</creatorcontrib><creatorcontrib>Cuzin, L.</creatorcontrib><creatorcontrib>Dat’AIDS group</creatorcontrib><title>Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France</title><title>Médecine et maladies infectieuses</title><addtitle>Med Mal Infect</addtitle><description>•We aimed to describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 as well as patients’ characteristics related to the use of protease inhibitors in 2015. We extracted data from 15,897 patients who started a first antiretroviral therapy between 2005 and 2015. Before 2014, 60% of initial treatment regimens were based on boosted protease inhibitors. The use of integrase strand transfer inhibitors as first-line treatments was recommended in 2014, and they have since been gradually replacing boosted protease inhibitors in the first-line treatment setting. In 2015, boosted protease inhibitors were still more frequently prescribed to young women, patients with high viral loads, and patients low CD4 cell counts.
To describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 and patients’ characteristics related to the use of protease inhibitors in 2015.
We extracted all patients starting ART between 2005 and 2015 from a large prospective cohort. Regimens were classified as three nucleoside reverse transcriptase inhibitors (NRTI), or two NRTIs with a boosted protease inhibitor (bPI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI), or with an INSTI. Patients’ characteristics at the time of initiation were collected. A multinomial logit model was fitted to analyze characteristics related to the choice of regimen in 2015.
We analyzed data from 15,897 patients. The proportion of patients starting with (i) a bPI decreased from 60% before 2014 to 38.1% in 2015; (ii) an NNRTI decreased from 30% to 17.8% in 2015; (iii) an INSTI gradually increased to 39.4% in 2015. In 2015, patients with an initial viral load ˃5 log copies/mL were less likely to receive NNRTI (OR=0.08) or INSTI regimens (OR=0.69) than bPIs. Patients with initial CD4+ T cell count ˂200/mm3 were less likely to receive an NNRTI (OR=0.28) or an INSTI regimen (OR=0.52) than a bPI. Women were less likely to receive an NNRTI (OR=0.79) or an INSTI regimen (OR=0.71) than a bPI; although this depended on age.
The use of bPI as first-line ART declined sharply in France from 2005 to 2015. bPI remained of preferential use in patients with high viral load, low CD4+ T cell count, and in women.
Décrire les choix de premier traitement antirétroviral en France entre 2005 et 2015 et analyser les caractéristiques liées à l’utilisation d’inhibiteurs de protéase (IP) en 2015.
Tous les patients ayant débuté leur traitement entre le 01/01/2005 et le 31/12/2015 et suivis dans la cohorte Dat’AIDS ont été inclus. Les schémas thérapeutiques ont été classés comme suit : trois analogues nucléosidiques (NRTI), deux NRTI avec un IP boosté (IPb), avec un analogue non nucléosidique (NNRTI) ou avec un inhibiteur de l’intégrase (INSTI). Les caractéristiques des patients à l’instauration du traitement ont été recueillies. Un modèle multinomial a été construit afin d’analyser les caractéristiques liées à la prescription d’IPb en 2015.
Au total, 15 897 patients analysés. La proportion de patients recevant un IPb est passée de 60 % avant 2014 à 38,1 % en 2015 et celle recevant un NNRTI a diminué de 30 % à 17,8 % en 2015. L’utilisation d’INSTI a progressivement augmenté jusqu’à 39,4 % en 2015. En 2015, les patients ayant une charge virale>5 log/mL recevaient moins souvent un NNRTI (OR=0,08) ou un INSTI (OR=0,69) qu’un IPb. Les patients ayant moins de 200 CD4/mm3 recevaient moins souvent un NNRTI (OR=0,28) ou un INSTI (OR=0,52) qu’un IPb. Les femmes recevaient moins souvent un NNRTI (OR=0,79) ou un INSTI (OR=0,71) qu’un IPb, cela dépendait aussi de leur âge.
L’utilisation d’IPb a significativement diminué au cours de la dernière décennie, mais reste préférée en cas de CD4 bas, de charge virale élevée ou chez les femmes.</description><subject>Adult</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active - statistics & numerical data</subject><subject>Cohort Studies</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>History, 21st Century</subject><subject>HIV</subject><subject>HIV infection</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infection par le VIH</subject><subject>Inhibiteurs d’intégrase</subject><subject>Initial HIV therapy</subject><subject>Integrase strand transfer inhibitors</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Practice Patterns, Physicians' - history</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Practice Patterns, Physicians' - trends</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Traitement antirétroviral initial</subject><subject>Viral Load</subject><issn>0399-077X</issn><issn>1769-6690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2LFDEQxYMo7rj6H4jk6B56rHxMp3NRlsF1hQEvit5CdbrGztAfY5IZ2P_eDL3u0VPg5fdeUfUYeytgLUDUHw7rkboRh7UE0RRpDbB5xlbC1LaqawvP2QqUtRUY8-uKvUrpACALCy_ZlQINdqPFio0_--B7jlMOkXKczyHikHjq59PQ8Zb4MVLyMbTUcUx8H2LK1RAm4jkS5pGmnD7xbY_Tb0p8PlPkuS8uTJkL4A-EMfEw8buIk6fX7MW-xNObx_ea_bj7_H17X-2-ffm6vd1VXmuZK9N12tSkWoNC672Sja1RoUSUrdCyg7JGi9oKsWkVNbq2xhhL3hphTdO06prdLLk9Du4Yw4jxwc0Y3P3tzl00ULIWSsizKOz7hT3G-c-JUnZjSJ6GASeaT8lJoaSUeqOaguoF9XFOKdL-KVuAu5TiDm4pxV1KuaillGJ79zjh1JbvJ9O_FgrwcQGo3OQcKLrkA5V7daUUn103h_9P-As9s536</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Pugliese, P.</creator><creator>Joly, V.</creator><creator>Valantin, M.A.</creator><creator>Cotte, L.</creator><creator>Huleux, T.</creator><creator>Allavena, C.</creator><creator>Reynes, J.</creator><creator>Poizot-Martin, I.</creator><creator>Bani-Sadr, F.</creator><creator>Cuzin, L.</creator><general>Elsevier Masson SAS</general><general>Elsevier Masson</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-6345-497X</orcidid></search><sort><creationdate>201906</creationdate><title>Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France</title><author>Pugliese, P. ; Joly, V. ; Valantin, M.A. ; Cotte, L. ; Huleux, T. ; Allavena, C. ; Reynes, J. ; Poizot-Martin, I. ; Bani-Sadr, F. ; Cuzin, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-7dd476e3b7a144f32896a3a2aa2b142d0201ba49115b3e84697779ec9719788b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active - statistics & numerical data</topic><topic>Cohort Studies</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>History, 21st Century</topic><topic>HIV</topic><topic>HIV infection</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infection par le VIH</topic><topic>Inhibiteurs d’intégrase</topic><topic>Initial HIV therapy</topic><topic>Integrase strand transfer inhibitors</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Practice Patterns, Physicians' - history</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Practice Patterns, Physicians' - trends</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Traitement antirétroviral initial</topic><topic>Viral Load</topic><toplevel>online_resources</toplevel><creatorcontrib>Pugliese, P.</creatorcontrib><creatorcontrib>Joly, V.</creatorcontrib><creatorcontrib>Valantin, M.A.</creatorcontrib><creatorcontrib>Cotte, L.</creatorcontrib><creatorcontrib>Huleux, T.</creatorcontrib><creatorcontrib>Allavena, C.</creatorcontrib><creatorcontrib>Reynes, J.</creatorcontrib><creatorcontrib>Poizot-Martin, I.</creatorcontrib><creatorcontrib>Bani-Sadr, F.</creatorcontrib><creatorcontrib>Cuzin, L.</creatorcontrib><creatorcontrib>Dat’AIDS group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Médecine et maladies infectieuses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pugliese, P.</au><au>Joly, V.</au><au>Valantin, M.A.</au><au>Cotte, L.</au><au>Huleux, T.</au><au>Allavena, C.</au><au>Reynes, J.</au><au>Poizot-Martin, I.</au><au>Bani-Sadr, F.</au><au>Cuzin, L.</au><aucorp>Dat’AIDS group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France</atitle><jtitle>Médecine et maladies infectieuses</jtitle><addtitle>Med Mal Infect</addtitle><date>2019-06</date><risdate>2019</risdate><volume>49</volume><issue>4</issue><spage>264</spage><epage>269</epage><pages>264-269</pages><issn>0399-077X</issn><eissn>1769-6690</eissn><abstract>•We aimed to describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 as well as patients’ characteristics related to the use of protease inhibitors in 2015. We extracted data from 15,897 patients who started a first antiretroviral therapy between 2005 and 2015. Before 2014, 60% of initial treatment regimens were based on boosted protease inhibitors. The use of integrase strand transfer inhibitors as first-line treatments was recommended in 2014, and they have since been gradually replacing boosted protease inhibitors in the first-line treatment setting. In 2015, boosted protease inhibitors were still more frequently prescribed to young women, patients with high viral loads, and patients low CD4 cell counts.
To describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 and patients’ characteristics related to the use of protease inhibitors in 2015.
We extracted all patients starting ART between 2005 and 2015 from a large prospective cohort. Regimens were classified as three nucleoside reverse transcriptase inhibitors (NRTI), or two NRTIs with a boosted protease inhibitor (bPI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI), or with an INSTI. Patients’ characteristics at the time of initiation were collected. A multinomial logit model was fitted to analyze characteristics related to the choice of regimen in 2015.
We analyzed data from 15,897 patients. The proportion of patients starting with (i) a bPI decreased from 60% before 2014 to 38.1% in 2015; (ii) an NNRTI decreased from 30% to 17.8% in 2015; (iii) an INSTI gradually increased to 39.4% in 2015. In 2015, patients with an initial viral load ˃5 log copies/mL were less likely to receive NNRTI (OR=0.08) or INSTI regimens (OR=0.69) than bPIs. Patients with initial CD4+ T cell count ˂200/mm3 were less likely to receive an NNRTI (OR=0.28) or an INSTI regimen (OR=0.52) than a bPI. Women were less likely to receive an NNRTI (OR=0.79) or an INSTI regimen (OR=0.71) than a bPI; although this depended on age.
The use of bPI as first-line ART declined sharply in France from 2005 to 2015. bPI remained of preferential use in patients with high viral load, low CD4+ T cell count, and in women.
Décrire les choix de premier traitement antirétroviral en France entre 2005 et 2015 et analyser les caractéristiques liées à l’utilisation d’inhibiteurs de protéase (IP) en 2015.
Tous les patients ayant débuté leur traitement entre le 01/01/2005 et le 31/12/2015 et suivis dans la cohorte Dat’AIDS ont été inclus. Les schémas thérapeutiques ont été classés comme suit : trois analogues nucléosidiques (NRTI), deux NRTI avec un IP boosté (IPb), avec un analogue non nucléosidique (NNRTI) ou avec un inhibiteur de l’intégrase (INSTI). Les caractéristiques des patients à l’instauration du traitement ont été recueillies. Un modèle multinomial a été construit afin d’analyser les caractéristiques liées à la prescription d’IPb en 2015.
Au total, 15 897 patients analysés. La proportion de patients recevant un IPb est passée de 60 % avant 2014 à 38,1 % en 2015 et celle recevant un NNRTI a diminué de 30 % à 17,8 % en 2015. L’utilisation d’INSTI a progressivement augmenté jusqu’à 39,4 % en 2015. En 2015, les patients ayant une charge virale>5 log/mL recevaient moins souvent un NNRTI (OR=0,08) ou un INSTI (OR=0,69) qu’un IPb. Les patients ayant moins de 200 CD4/mm3 recevaient moins souvent un NNRTI (OR=0,28) ou un INSTI (OR=0,52) qu’un IPb. Les femmes recevaient moins souvent un NNRTI (OR=0,79) ou un INSTI (OR=0,71) qu’un IPb, cela dépendait aussi de leur âge.
L’utilisation d’IPb a significativement diminué au cours de la dernière décennie, mais reste préférée en cas de CD4 bas, de charge virale élevée ou chez les femmes.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>30409541</pmid><doi>10.1016/j.medmal.2018.10.005</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6345-497X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0399-077X |
| ispartof | Médecine et maladies infectieuses, 2019-06, Vol.49 (4), p.264-269 |
| issn | 0399-077X 1769-6690 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03261312v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - therapeutic use Antiretroviral Therapy, Highly Active - statistics & numerical data Cohort Studies Drug Therapy, Combination Female France - epidemiology History, 21st Century HIV HIV infection HIV Infections - drug therapy HIV Infections - epidemiology HIV Protease Inhibitors - therapeutic use Human health and pathology Humans Infection par le VIH Inhibiteurs d’intégrase Initial HIV therapy Integrase strand transfer inhibitors Life Sciences Male Middle Aged Practice Patterns, Physicians' - history Practice Patterns, Physicians' - statistics & numerical data Practice Patterns, Physicians' - trends Reverse Transcriptase Inhibitors - therapeutic use Traitement antirétroviral initial Viral Load |
| title | Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20antiretrovirals%20should%20be%20prescribed%20as%20first-line%20treatments?%20Changes%20over%20the%20past%2010%20years%20in%20France&rft.jtitle=Me%CC%81decine%20et%20maladies%20infectieuses&rft.au=Pugliese,%20P.&rft.aucorp=Dat%E2%80%99AIDS%20group&rft.date=2019-06&rft.volume=49&rft.issue=4&rft.spage=264&rft.epage=269&rft.pages=264-269&rft.issn=0399-077X&rft.eissn=1769-6690&rft_id=info:doi/10.1016/j.medmal.2018.10.005&rft_dat=%3Cproquest_hal_p%3E2132224538%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2132224538&rft_id=info:pmid/30409541&rft_els_id=S0399077X17305449&rfr_iscdi=true |